Why Whitehawk Therapeutics, Inc.’s (WHWK) Stock Is Down 6.37%
As of Tuesday, August 11, Whitehawk Therapeutics, Inc.’s WHWK share price has dipped by 6.37%, which has investors questioning if this is right time to buy.Michael Rose
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Michael Rose
Rosalio Madrigal
Rosalio Madrigal
Michael Rose
Jenna Brashear
| Share Statistics | WHWK | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $264.0 | $289.2 | 30% |
|
| Shares Out (Mil) | 82.9 | 54.1 | 58% |
|
| Institutional Ownership | 81.9% | 93.1% | 50% |
|
| Float (Mil) | 28.7 | 42.2 | 35% |
|
| Beta | 0.78 | 0.94 | 46% |
|
| Avg Daily Volume (000s) | 211 | 451 | 46% |
|
| Price Change (52-week) |
155.8% | 59.8% | 96% |
|
| Growth | WHWK | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (13.4%) | 14.1% | 4% |
|
| Net Income (5yr) | (42.5%) | (10.1%) | 9% |
|
| EPS (5yr) | 28.3% | 15.9% | 79 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 15.2% | (15.6%) | 73% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 2 | 3 | |
| Current EPS | ($0.247) | ($0.965) | ($0.987) | |
| Month Ago EPS | ($0.268) | ($1.110) | ($1.103) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 2 | 1 | 1 | |
| Three Months Ago EPS | ($0.300) | ($1.165) | ($1.225) | |
| Year/Year Chg | 22.9% | 189.8% | 236.3% | |
| Financials | WHWK | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($80) | ($43) | 13% |
|
| EPS (TTM) | ($1.098) | ($1.500) | 20% |
|
| Operating Cash Flow (TTM) (Mil) | ($69) | ($31) | 8% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $86 | $190 | 20% |
|
| Valuation | WHWK | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.44 | 2.84 | 37% |
|
| P/E | na | 20.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | WHWK | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (42.6%) | (47.8%) | 13% |
|
| ROE | (45.0%) | (55.0%) | 16% |
|
| Liabilities to Assets | 5.7% | 29.7% | 3% |
|
| F-Score | 1 | 3 | na |
|
Whitehawk Therapeutics, Inc. did not pass any screens on 9/3/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors